Novel second messenger offers drug development opportunities.
Senior
Kathryn
K
D000818:Animals; D002766:Cholecystokinin / Q000494:pharmacology; D003922:Diabetes Mellitus, Type 1 / Q000209:etiology; D015195:Drug Design; D005260:Female; D006801:Humans; D009249:NADP / Q000031:analogs & derivatives* / Q000502:physiology*; D015290:Second Messenger Systems / Q000502:physiology*; D014590:Uterine Contraction / Q000502:physiology
D009249:NADP; C024376:NAADP; D002766:Cholecystokinin